Introduction
Administering aerosolized medications to patients receiving noninvasive ventilation (NIV) is a common practice in critically ill patients with acute respiratory failure because it has demonstrated a clear clinical benefit [1, 2] . Advances in aerosol technology have improved drug delivery efficiency during NIV [3] . In healthy subjects during NIV vibrating mesh nebulizers (VMN) delivered > 3-fold more radiolabeled drug into the respiratory tract compared with conventional jet nebulizers (JN) [4] . Clinical evaluation of the efficacy of aerosol therapy during NIV in the treatment of acute exacerbation of COPD (AE COPD) is very limited [5] .
Methods
•30 patients treated with NIV for AE COPD. 
Results
•The degree of change between groups in Borg dyspnea score was significantly reduced with VMN (5.9±1.1 to 4.1±1.17) than JN (6.2±1.2 to 5.2±1.2; p=0.0006) after 4 hours.
•A reduction in respiratory rate (baseline to 4h) from 21.9±1.9 to 19.3±1.4 b/min vs 22.3±2.0 to 20.8±1.64 b/min was observed; with VMN and JN, respectively; p=0.0003), and the degree of change was significantly reduced with VMN.
•All PFTs, SpO 2 , PaO 2 and PaCO 2 parameters improved in both groups, but overall changes from baseline to 4 hours were greater with VMN than JN, especially for FVC (110 mL vs 400 mL).
Conclusions
Bronchodilator administration during NIV with VMN in patients with AE COPD resulted in clinically significant improvements in PFTs and a significant improved Borg dyspnea score. Additional studies are required to determine impact on clinical outcomes.
Aim
To compare efficacy of bronchodilators administered via a VMN and JN during NIV in patients with AE COPD 
